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Myriads of epigenomic features have been comprehensively profiled in health and disease across cell types, 
tissues and individuals. While current epigenomic approaches can infer function for chromatin marks 
through correlation, it remains challenging to establish which marks actually play causative roles in gene 
regulation and other processes. After revisiting how classical approaches have addressed this question in 
the past, we review the current state of epigenomic profiling and how functional information can be 
indirectly inferred. Subsequently, we present new approaches promising definitive functional answers 
collectively referred to as “epigenome editing”.  In particular, we explore CRISPR-based technologies for 
single- and multi-locus manipulation. Finally, we discuss which level of function can be achieved with 






Non-genetic factors contribute to many cellular functions, traits and phenotypes 1. Among the first to 
recognize this conceptually was Conrad Hal Waddington who coined the term “epigenetics” in 1942 to 
describe molecular mechanisms “by which the genes of the genotype bring about phenotypic effects” 2. 5 
Captured by the iconic image of the epigenetic landscape (Figure 1A), he imagined its mode of action to 
be “causal” 2, similar to the presumed deterministic effect a topographic shape has on the movement of a 
marble 3.  
 
Half a century later, we have come a long way in our understanding of the molecular basis of epigenetics 10 
and its role in cellular and organismal plasticity and dynamics. A number of ground-breaking studies have 
revealed that alterations to chromatin, the nuclear complex of macromolecules consisting of DNA, protein 
(histones), and RNA, can in some cases account for changes in gene expression (for a selection of classic 
experiments concerning DNA methylation see Box1). For the purpose of this review, we therefore define 
modifications of DNA and histones as alterations to chromatin but distinguish between chromatin marks 15 
(individual chemical modifications) and features (multiple linked modifications and more complex 
elements). 
 
Catalogs of chromatin marks and features obtained from cells and tissues at different stages of development 
and disease states have since become an extremely useful resource. Epigenomic profiling was the key to 20 
discover many significant associations between chromatin features and genomic function at the level of 
gene regulation and expression, cell identity, age and even disease 4-6. However, correlation does not 
necessarily imply causation, and technical limitations had previously not allowed the interrogation of 
individual or combination of marks to test for direct functional effects. The majority of research 
consequently focused on identifying what Adrian Bird defined as the unifying definition of epigenetic 25 
events: “the structural adaptation of chromosomal regions” that may "register, signal or perpetuate altered 
activity states” 7. Today epigenetic research is at a turning point. New approaches, benefiting from the 
remarkable developments in genome editing, enable us to move forward and finally elucidate which 
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individual chromatin marks or features play causal roles in processes such as gene regulation, cellular 
memory, cellular differentiation and disease aetiology 8. 
 
The term “function” or “functional” means different things to different people and, in our view it is at times 
incorrectly used in the literature. For clarification and in the context of this review, we therefore 5 
differentiate between two levels of function - inferred and causal - as illustrated in Figure 2. Inferred 
function is usually based on correlation of aggregated marks or features with observed effects, e.g. gene 
activity states or phenotypes, but cannot establish whether marks play truly causal roles. In contrast, causal 
function is based on direct evidence of individual marks or features driving the expression of a particular 
gene or regulating a particular phenotype.  10 
 
Throughout this review, we will emphasise the level of function that can or has been demonstrated using 
different experimental approaches. We will discuss what can be learned from comparative chromatin 
profiling, and how associations of chromatin marks with phenotypes can identify candidate regions for 
functional testing. While fully appreciating the importance of plant epigenomics and associated resources 15 
9-13, this review will focus on mammalian chromatin. We will briefly revisit insights gained from early 
knockout studies but mainly concentrate on recent epigenome editing approaches 14 (sometimes also 
referred to as epigenetic engineering 15), which test causality directly. A short overview of methods for 
epigenome editing will be provided. However, for a more detailed discussion of technology aspects, we 
refer the reader to excellent recent reviews on genome and epigenome editing 16-18. Finally, we will 20 
speculate how these approaches could be used to efficiently deduce causal function from profiles in the 
future. While we recognize the importance of differential expression and binding of transcription factors, 
nucleosome positioning and chromatin remodelers to gene regulation (thoroughly reviewed previously)19-
21, we will focus mostly on the contribution of chromatin marks to gene expression.  
 25 




Following the completion of the Human Genome Project 22 it became immediately evident that additional 
efforts would be required to understand how complex genomes are regulated. Driven by different 
technologies, new international resources (see online links for details) were soon established to profile all 
aspects of the genome and epigenome that were thought to have functional relevance. Collectively, these 
resources have increased the amount of data per sample we now have over and above the genome by several 5 
orders of magnitude. 
 
Projects and Data types 
 
Starting in 2003, ENCODE (Encyclopedia of DNA Elements) was the first international project employing 10 
large-scale epigenomic profiling to identify regulatory elements in the human genome. ENCODE pioneered 
many of the required technologies (e.g. for profiling histone modifications) and focused on cell lines rather 
than tissues or primary cells. The project was subsequently expanded to include model organisms 
(modENCODE), adding the power of comparative epigenomics to the effort. ENCODE became a member 
of the International Human Epigenome consortium (IHEC), a project launched in 2010, which aims to 15 
generate 1,000 reference epigenomes in primary tissues and cell types and has become the umbrella 
organisation under which national and international epigenome efforts are jointly coordinated. IHEC 
currently has 9 members, ENCODE (USA), Roadmap Epigenomics (USA), BLUEPRINT (EU), DEEP 
(Germany), Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC; Canada), 
Core Research for Evolutional Science and Technology (CREST; Japan) and the national epigenome 20 
projects from Korea, Singapore and Hong Kong (see online links for details). Within the context of this 
review, the key IHEC achievements to date are the introduction and implementation of the IHEC quality 
standards for epigenomic data and the IHEC data portal which provides access to the data of all IHEC 
projects. At the time of writing, over 7,000 data sets from over 350 tissues and cell types were available 
including 198 complete and 847 partially complete reference epigenomes. Based on highly successful pilot 25 
projects 23, these data will soon be complemented by a new international effort (4D Nucleome), which aims 
to produce three dimensional maps of mammalian genomes and to develop predictive models to infer 
function from mammalian genome architecture. As discussed in the following sections, integration of 
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epigenomic features with genetic variation (e.g. from the Catalog of published genome-wide association 
studies (GWAS Catalogue)), gene expression (e.g. from the Genotype–Tissue Expression (GTEx) project) 
and other data is tremendously useful to pinpoint candidate variants for functional analysis. However, one 
limitation hampering fast exploitation of these resources for functional and other analyses today is that 
much of the raw data are not available under open access and require prior approval by a Data Access 5 
Committee (DAC).  
 
The descriptive data types that can be obtained by epigenomic profiling are still growing both in numbers 
and complexity. Figure 3 illustrates this complexity of profiles and Box 2 provides details on the individual 
marks and features profiled to date. These can be divided into the following categories: DNA modifications, 10 
which includes C5-methylcytosine (5mC), the first and best studied epigenomic modification discovered 
in 1948 24 as well as N6-methyladenine (6mA), which was only recently reported 25. Accounting for 
oxidation products of 5mC as well as 3mC and 6mA, there are currently six different known epigenomic 
modifications on the DNA level but this number is likely to increase in the future and analysis of their 
chemical and biological functions is subject of intense ongoing research 26, 27.  Histone modifications 15 
represent by far the largest category among profiled chromatin marks. With currently 12 known chemical 
modifications, which can occur at over 130 post-translational modification sites 28 on five canonical and 
some 30 histone variants, the theoretical number of combinatorial possibilities is truly astronomical 29 and 
consequently our knowledge about their functional roles is still limited 30, 31. For some commonly studied 
marks, however, correlations between their presence and the activity of different genomic elements are 20 
apparent (e.g. methylation of H3K9 and H3K27 at inactive (or poised) promoters, methylation of H3K4 
and acetylation of H3K27 on active enhancers and promoters, and methylation of H3K36 in transcribed 
gene bodies; for a more comprehensive view, see “ the ‘dashboard’ of histone modifications” from Zhou 
and colleagues 30). Profiling of nucleosome occupancy along the genome can reveal regions of open 
chromatin that may have gene regulatory function. Interestingly, common trait-associated single-nucleotide 25 
polymorphisms (SNPs) identified through GWAS approaches frequently lie outside coding regions but fall 
into DNase1-hypersensitive sites (DHSs), where they are thought to regulate distal genes 32. Profiling of 
RNA modifications on coding and non-coding RNAs is less advanced, due to technological limitations. 
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While more than 100 different RNA modifications are known 33, and new ones are continuously being 
discovered 34-36, they have not yet been comprehensively profiled across the transcriptome 33, 37. Further 
advanced is the systematic profiling of chromatin architecture, which only recently became technically and 
economically feasible. Projects, such as the 4D Nucleome mentioned above, aim to link genetic and 
epigenomic variants to enhancers and promoters they interact with in three dimensional space; thereby 5 
defining gene-set interactomes and pathways as new candidates for functional analysis and therapeutic 
targeting. Such local short-range interactions have been shown to aggregate into higher-order chromatin 
domains, which can themselves play functional roles 38.  
 
Data integration and interpretation  10 
 
A large variety of different marks and features have been profiled to date, resulting in an amount of 
published epigenomic data that can easily be overwhelming. Taken together, comparative approaches have 
resulted in reliable information about the composition and plasticity of mammalian epigenomes during 
development and disease. But without additional context, it remains difficult to predict from these 15 
descriptive data which of the large number of marks, features and profiles are most indicative for causal 
and quantitative effects (Figure 2). Consequently, next-generation approaches for the integration and 
interpretation of chromatin features attract high interest. IHEC, for example, has identified a subset of nine 
required profiles and assays (Figure 3) for the generation of so-called reference epigenomes in order to 
bundle obtained epigenomic data and to maximize its potential to infer function. The rapidly growing 20 
number of reference epigenomes registered in EpiRR (see online links) constitutes an ideal starting point 
for integrative analysis. More recent approaches using high-level epigenomic data integration have been 
pioneered by the Roadmap Epigenomics Project and applied to 111 human epigenomes so far 39. Typically, 
such integrated data sets consist of 20-50 genome-wide profiles making up a multi-dimensional data matrix 
as illustrated in Figure 4. To ensure consistency across the matrix, novel methods such as ChromImpute 25 
have been developed for large-scale imputation of epigenomic data 40 resulting in several improvements: 
detection of low-quality data, inference of missing data, and, as a consequence, a more accurate and 




For the interpretation of such complex data, multi-dimensional matrices can then be aggregated or collapsed 
into a small number of chromatin states using computational programs e.g. ChromHMM 41 or Segway 42, 43 
which have been trained on a variety of datasets, resulting in  chromatin state annotation with inferred 
function (including “promoter”, “enhancer”, “insulator”, “transcribed” or “repressed”) at a particular 5 
genomic locus. Several of such inferred enhancers defined by strong H3K4 methylation and weak signals 
of RNA polymerase II (RNAPII) occupancy have been experimentally validated 41. Furthermore, chromatin 
states have also been used in combination with Hi-C interaction maps to predict individual and cell type-
specific enhancer–promoter interactions using TargetFinder 44. Based on these and many more specialized 
tools such as Epigram, epiGRAPH, Epilogos, eFORGE, Epigwas, ChromNet and the Epigenetic Clock (see 10 
online links for details), complex chromatin maps can be further segmented.  
 
In the context of disease, recent examples using integrative epigenomic analysis include the discovery of 
pathogenic rewiring of cell-type specific enhancer circuits in obesity 45 and type 1 diabetes 46, as well as 
the finding that epigenomic changes accompany innate immunity in humans 47. Of these, the first study 45  15 
best exemplifies the profiles-to-function approach (termed P2F) presented here. Using integrative analysis 
as illustrated in Figure 4, the authors predicted the cell type and regulatory element (enhancer) in and 
through which a genetic variant identified by GWAS was likely to exert its function in fat mass and obesity 
(FTO)-associated obesity.  They achieved this by mapping GWAS-identified risk variants onto chromatin 
state annotation generated from profiling 127 human cell types to predict the regulatory nature of the target 20 
region and the cell type in which this region would most likely be functional. They then used haplotype-
specific enhancer assays to validate the enhancer status of the predicted element, Hi-C to link the predicted 
enhancer to two target genes involved in early adipocyte differentiation and expression quantitative-trait-
locus (eQTL) analysis in primary human adipocytes from risk-allele and non risk-allele carriers to assess 
changes in gene expression. Finally, they restored correct expression of the affected target genes in cells 25 
isolated from patients and a mouse model using CRISPR-Cas9 genome editing.  In this case, a genetic 
variant was shown to be causally involved in a pathway for adipocyte thermogenesis regulation linked to 
pro- and anti-obesity effects. There is no reason why the same P2F approach in combination with 
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epigenome editing as outlined below should not work equally well for elucidating causal functions of 
epigenomic modifications and variants. Indeed, first attempts following this strategy using a general 
pipeline are extremely encouraging but existing experimental and computational limitations as well as 
currently unknown challenges will have to be overcome as the field moves forward 48. Together with many 
other studies, these profiling and data integration efforts have resulted in a fantastic resource that already 5 
allows us to infer which marks and features may be functional and forms the starting point for future 
analyses of causal function. 
 
Towards genetic analysis of causality 
 10 
Epigenomic profiling has aided the discovery of a plethora of orchestrated chromatin changes that occur 
during development and disease. Data integration enables these candidate sites to be reduced to a subset 
with inferred function (Figure 2). The experimental validation of their relevance, however, remains 
difficult. To some extent, genetic approaches have successfully provided evidence for the importance of 
chromatin marks. Here we will discuss two widely used approaches: genetic manipulation of the DNA 15 
domains underlying an epigenomic feature; and genetic manipulation of the enzymes responsible for their 
establishment or removal. 
 
Genetic manipulation of sites of chromatin marks or features 
 20 
Individual epigenomic features can be removed through manipulation of the underlying DNA sequence. 
While it is possible to mutate or delete single bases harbouring DNA modifications, this approach is not 
applicable to histone modifications or larger epigenomic features. In many cases, entire genomic domains 
containing the feature of interest have to be excised instead. Gene targeting has been an exceptionally 
successful approach to functionally link several epigenetic mechanisms (DNA methylation, chromatin 25 
insulation, noncoding transcription) to genomic imprinting 49-52. However, in most cases, genetic 
manipulation only provides indirect evidence for causality (Figure 2), since functional consequences could 
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be attributed just as well to the loss of the genomic DNA sequence rather than to the loss of the epigenomic 
feature.  
 
Today, genetic manipulation is often still the only available option for conducting functional experiments 
(e.g. Fanuci et al.53). Improved methods using targetable nucleases 54 have made it easier to experimentally 5 
generate precise modifications of genetic sequence. Such approaches have been successfully used to 
interrogate enhancer regions 55-59 and to investigate the function of local chromatin architecture. As 
mentioned in Box 2 and Figure 3, local chromatin architecture can be profiled and segmented into 
topologically associating domains (TADs), whose boundaries appear to be genetically defined by 
orientation-specific CTCF binding sites. Genetic inversion of CTCF binding sites has been used to shift 10 
domain boundaries at the protocadherin gene cluster, leading to a re-configuration of enhancer–promoter 
interactions and to reduced expression of some of the associated genes 60. Likewise, a TAD structure at the 
EPHA4 locus was modified in a mouse model by introducing deletions and inversions that mimic those 
observed in patients with limb malformations 38.  
 15 
While in these above examples a handful of candidate features within small and well defined regions 
(imprinted domains, individual enhancers or single topological domains) were manipulated, most 
epigenomic profiles contain many hundreds or thousands of candidate marks distributed across the entire 
genome. A strategy for how genetic manipulation can nevertheless be used to interrogate many epigenomic 
candidate sites at once was recently introduced 61. Korkmaz et al. integrated different published chromatin 20 
profiles (e.g. H3K4me2, H3K27ac) and transcription factor binding sites to generate a candidate list of 
active enhancers bound by p53. To reveal which of these enhancers are necessary for a specific function of 
p53, namely induction of oncogene-induced senescence, the authors introduced targeted mutations in 685 
regions and found that surprisingly most of the p53-bound enhancers were dispensable for triggering 
senescence. Instead they were able to show that only two genomic binding-sites of p53 are mandatory for 25 
this disease-relevant mechanism 61. 
 
Genetic manipulation of chromatin modifying enzymes 
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While generally successful in attributing causal function to genomic domains hosting epigenomic marks 
and features, the aforementioned approaches cannot establish how large the contribution of epigenetics to 
the observed effects is. A second experimental strategy using genetic targeting, namely deletion or mutation 
of chromatin modifying enzymes, overcomes this drawback and thus was most instrumental in 
demonstrating their participation in gene regulation. Epigenetic model systems applicable to early 5 
embryogenesis or embryonic stem (ES) cell based experiments (amongst others: genomic imprinting and 
retro-transposon silencing) were especially useful to attribute crucial roles to chromatin modifications, 
since those allowed to study the acute effect that loss of certain chromatin marks (e.g. H3K9 methylation 
and DNA methylation) had on the expression of candidate loci (imprinted genes and retro-transposons, 
respectively) 62-65. Moreover, knockout studies have been able to clearly establish that a large variety of 10 
chromatin modifying enzymes are essential for normal animal development as their loss induces embryonic 
lethality, sometimes quite early (for example Dnmt1 66, Dnmt3a and Dnmt3b 67, G9a 68, Suv39h1 and 
Suv39h2 69, Hdac1 70, Ezh2 71, SetDB1 72 or LSD1 73). However, these experiments are less informative 
about the frequency of functional chromatin marks. Embryogenesis is a highly complex process, which can 
be disturbed in many ways. Loss of expression of single proteins can easily trigger lethality (even early 74, 15 
75). Consequently, it is difficult to deduce functional relevance of individual marks from the elimination of 
many thousands. Beyond the difficulties in distinguishing the local versus global epigenomic consequences 
when chromatin modifying enzymes are mutated (or pharmacologically inhibited), there are more aspects 
to consider. Chromatin modifying enzymes have a much larger range of substrates than is often presumed. 
Most, if not all, histone modifying enzymes possess non-histone targets as well 76, 77. Therefore, resulting 20 
embryonic phenotypes cannot always be attributed to misregulation of histone marks alone.  
 
Embryonic lethality arising from germline depletion of genes can be circumvented by conditional 
knockouts. This strategy has been so successfully applied to chromatin modifying enzymes that they can 
be discussed here only incompletely. The well-studied hematopoietic 78-82, muscular 83 and cardiac 84, 85 25 
systems are typical examples which have been used to show the crucial roles played by DNA methylation 
78-80, H4K20 methylation 83, H3K27 methylation 81, 82, 84 and histone acetylation 85 in somatic stem cell 
homeostasis, lineage specification or progression. It should, however, also be mentioned that detected 
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phenotypes in such studies are hardly driven by de-regulation of a multitude of genes as they are often 
surprisingly specific (e.g. affecting only certain lineage choices 78, 81 or cellular phenotypes 83) and in some 
cases have even been rescued by normalizing expression levels of single genes 82-84.  
 
While these observations of focused transcriptional consequences and specific phenotypes can in many 5 
cases be explained by incomplete loss of chromatin marks or widespread compensation by redundant 
chromatin complexes, it could also indicate that only a small number of chromatin marks mediate functional 
effects large enough to cause cellular phenotypic changes and that those might strongly depend on the 
cellular context. Consistent with this is the notion that homeostatic cells often remain relatively unaffected 
from pharmacological inhibition of chromatin modifying enzymes, while many cancer cells show an 10 
enhanced “epigenetic vulnerability” (for a concise review see Dawson et al.86). Another example is the 
finding that, in vitro, even global loss of canonical epigenetic marks does not necessarily result in major 
transcriptomic changes. The (almost) complete loss of DNA methylation 87, H3K27me3 88 or an artificial 
induction of H3K4me3 marks 89 in ES cells, for instance, results only in minor transcriptional changes, 
despite affecting their differentiating progeny. Taken together these data indicate that a majority of 15 
epigenetic marks may not play decisive roles in stable cell populations and that the causality of chromatin 
marks is only revealed when accompanied by major cellular transitions such as differentiation, 
reprogramming or transformation. An alternative (but not mutually exclusive) explanation would be that 
many chromatin marks in the epigenome have opposing causal roles, which are often “canceled out” when 
marks are globally altered, implicating more pronounced phenotypes when the manipulation of chromatin 20 
modifications is restricted to few individual loci. In summary, genetic manipulation of chromatin modifying 
enzymes has been crucial to implicate their causal involvement in many biological processes; however the 
functional involvement of individual chromatin marks can mostly still only be inferred (Figure 2).  
 
Site-specific epigenome editing   25 
 
Recruitment of chromatin-modifying enzymes to specific loci 
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The genetic experiments described above indicate that only a fraction of marks detected in epigenomic 
profiles may play direct causal roles (Figure 2). Consequently, new experimental approaches able to test 
the causality of individual epigenetic marks directly are in high demand. Several new approaches are 
currently emerging including the exploitation of naturally occurring or engineered histone mutations 90, 91 
or targetable chromatin remodelers 92. Another approach is the fusion of chromatin-modifying enzymes (or 5 
catalytic domains) to targetable DNA binding domains which has made it possible to change single 
chromatin marks at particular genomic sites. This constitutes a substantial technological advance, as it is 
now possible to interrogate the function of individual marks instead of removing underlying DNA 
sequences or all instances of a particular mark across the entire genome by genetic or pharmacological 
approaches. There is now a range of systems that allow targeting of a chromatin-modifying enzyme to 10 
specific DNA sequences by fusing it to either a zinc finger, a transcription activator-like effector (TALE) 
or a catalytically inactive variant of the bacterial Cas9 nuclease (dCas9). Specifying the genomic target 
sequence using zinc finger or TALE architectures involves assembling multiple repetitive protein domains 
that each recognise a particular DNA base in the target sequence. In contrast, the CRISPR–Cas system can 
be targeted to a precise genomic location by specifying the base sequence of a part of a synthetic RNA 15 
known as the guide RNA (gRNA). Remarkably, Cas9 is able to target genomic sites, even when those are 
functionally silenced or structurally condensed, although this influences the dynamics of DNA recognition 
93. It is easier and faster to generate large numbers of gRNAs targeting different sequences than it is to 
assemble a large number of different zinc finger or TALE domains. The main advantage of the CRISPR–
Cas system for epigenomic editing thus lies in the ease of generating targeting constructs and its potential 20 
for multiplexing. 
 
Using these platforms to target chromatin-modifying enzymatic domains to particular sites in the genome 
enables testing whether individual chromatin marks have causal effects on gene expression (as illustrated 
in Figure 5a). In addition to more general transactivator and repressor proteins 94, a range of chromatin-25 
modifying enzymes have already been attached to DNA binding domains and shown to successfully add or 
remove chromatin marks at the target sites (Table 1). Collectively, these pioneering studies have shown 
that catalytic domains of chromatin-modifying enzymes can be sufficient to induce transcriptional changes 
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when directed to specific target sites. Adequate controls were included in most of these studies, including 
catalytic mutants which ensured that the observed effect is due to enzymatic activity and not merely due to 
chromatin binding. For example, demethylation of several sites in the RhoxF2 promoter leads to 
transcriptional up-regulation of this gene 95. Similarly, a dCas9–p300 histone acetyltransferase fusion has 
been used to activate transcription of MyoD and Oct4 from proximal promoters and distal enhancers. In 5 
many cases, induction of mRNA production achieved with dCas9–p300 is stronger than that achieved by a 
classical trans-activator domain without enzymatic activities (VP64) at the same site 94, 96. Additionally, 
lysine demethylase LSD1 has been shown to silence genes when targeted to known enhancer regions 14, 97 
while various targetable constructs of the DNMT3a DNA methyltransferase can decrease transcript levels 
when targeted to promoters 98-100. Thus, targetable chromatin modifiers have been used both to up- and 10 
down-regulate mRNA levels, providing direct evidence that chromatin modifier can regulate transcription. 
Whether the observed effects are exclusively mediated via epigenomic marks or whether local 
modifications of other chromatin proteins can sometimes contribute 101 has yet to be firmly established. 
Furthermore, effects on transcription are detected following modification of some, but not all, targeted sites. 
This indicates inherent differences in the regulatory potential of genomic loci and, consistent with results 15 
from genetic experiments, that certain chromatin marks may only be functionally relevant at a subset of 
sites at which they occur. To further investigate this it will be necessary to study how the catalytic activity 
of the chromatin modifier at a particular site impacts transcription and whether the engineered chromatin 
changes recruit known “readers” of chromatin marks.  
 20 
As discussed above, the term “function” can take different meanings ranging from inferred to causal, 
whereby the latter could manifest itself in several ways. Some epigenomic features might be dominant in 
their effect (e.g. affecting polymerase activities directly), while others might be dependent on certain pre-
requisites to reveal a functional involvement (e.g. transcriptional priming: poising the cellular response 
spectrum by forming a transcription factor binding platform for example) 19, 102. Thus, in some cases (and 25 
quite similar to most other biological mechanisms) the function of an epigenomic feature could depend on 
cell type, culture condition or developmental window studied. Furthermore, causal effects could also reveal 
themselves on several levels, as a change in transcript level, protein level, or cellular phenotype. It is often 
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difficult to judge whether statistically significant but sometimes relatively small engineered changes in 
transcript level are biologically relevant. However, it is encouraging that several studies have already 
achieved changes in protein level through epigenomic editing 98 97 103. Ultimately, however, it will be 
important to test directly whether engineered chromatin modifiers can influence cellular or organismal 
phenotypes. Some reports made such a connection already showing for example that addition or removal 5 
of single chromatin marks is sufficient to alter cell proliferation, colony-forming ability of cancer cells 98, 
the self-renewal of pluripotent stem cells 97 and even addiction-related behaviour in living mice 103.  
 
One important question that remains is how common such functional marks are and whether engineered 
changes can be sustained by cells and mitotically inherited. Although DNA methylation is thought to be 10 
the most heritable and stable mark, there is emerging evidence that cells may in fact counteract engineered 
changes. Engineered DNA methylation marks have been observed in some studies to reduce to background 
levels in vitro 104, 105 indicating they are actively or passively lost, while in another report, they were found 
to persist 106. Since the targeted sites differed (and in the latter case were located on a human artificial 
chromosome) it is possible that endogenous chromatin “context” determines whether an engineered change 15 
can be maintained, but this requires further investigation. If engineered changes are found to be transient 
— and this may need to be established independently for each type of chromatin modification at each 
targeted site — negative results with regard to functional effects have to be examined with care. Expression 
of the targetable chromatin modifier, engineered modifications, transcriptional and phenotypic changes 
should be monitored over time.  20 
 
Investigating quantitative contributions and hierarchies of regulatory epigenetic marks  
Now that tools to manipulate individual chromatin marks have become widely available, the time has come 
to move on from qualitative descriptions (“silencing”, “activating”) to comprehensively quantify the 
contribution of individual marks in defining endogenous transcriptional states. For this, it would be useful 25 
to establish a hierarchical order of these marks i.e. to elucidate which functional chromatin marks are 
primary triggers (influencing other epigenomic features) and which are usually occurring as secondary 
consequences. In this way, it would be possible to pinpoint the proportion of transcription that is strictly 
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defined by chromatin features, how other gene regulatory mechanisms (transcription factors, topological 
structure, noncoding transcription) are interlinked and where the molecular switches can be found that 
functionally turn genes on and off. 
 
To quantify the individual contribution of different epigenetic modifications, a large number of different 5 
types of engineered chromatin marks should be compared directly (Figure 5b). To allow this, epigenomic 
editing approaches should not solely concentrate on re-assessing the importance of well-studied chromatin 
marks and instead include some of those marks and features less comprehensivly analysed to date (depicted 
in Box 2). This requires, however, the swift development of a series of new engineering tools. In yeast, the 
first important steps in this direction have already been taken 107. Here, over 100 different chromatin factors 10 
were fused to the same zinc finger DNA binding domain targeting the promoter of a reporter gene. Some 
of the targeted proteins were found to act as activators, some as inhibitors, allowing subsequent ranking 
based on effect size, i.e. changes in protein expression in response to targeted chromatin modification 107. 
Studies in mammalian cells have not been as comprehensive so far but some recent publications followed 
a similar strategy already to compare the effects of a series of chromatin domains 108 and modifications 106 15 
on candidate genes in mammalian cells 94.  
 
Such approaches will be the basis to elucidate the hierarchical order of chromatin marks. Targeting more 
than one chromatin modification to the same locus will allow to elucidate which marks are causing others 
to change and which are functionally dominant, antagonistic, additive or synergistic. Sequential expression 20 
of dCas9–chromatin modifier constructs will show whether the timing of modifications is important in 
establishing chromatin states and, in combination with overexpression and knockdown constructs, will 
pinpoint the relationship of marks with other gene-regulatory mechanisms (such as transcription factors). 
Thus, expanding the molecular toolbox of epigenome editing will be of lasting benefit, due to the large 
amount of possible questions to tackle in the near future. 25 
 
Epigenome editing of higher-order chromatin architecture  
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Local chromatin architecture has been extensively manipulated by genomic targeting through deletions or 
mutation of regulatory regions, insulators and border elements (see for example 38, 49, 109, 110). Today, 
strategies are emerging that can alter domain boundaries without affecting the underlying genomic DNA 
sequence. While targetable CTCF proteins have not yet been reported to date, a zinc finger–Ldb1 fusion 
has been used already, to target the inactive β-globin locus in an erythroblast cell line lacking GATA1 111. 5 
Binding of Ldb1 induced the formation of a chromatin loop between the promoter and a locus control region 
and was sufficient to activate transcription of β-globin, although the expression levels did not reach wild-
type levels. A similar approach has been used to activate the expression of developmentally silenced fetal 
globin genes in mouse and human erythroid cells, which could have translational value for the treatment of 
sickle-cell anemia 111 10 
 
A vision for high-throughput epigenetic screens 
It has now been convincingly demonstrated that particular chromatin modifications can affect the 
expression of reporter loci and in some cases even endogenous genes. One of the pressing questions in 
epigenetics today is how much of the genome will be controllable in a similar way. The availability of a 15 
large spectrum of epigenome editing tools could in the future be used to screen for individual epigenomic 
marks which are either necessary or sufficient for specific cellular phenotypes (Figure 5c). This would 
require appropriate libraries of gRNAs, each targeting dCas9–chromatin modifying enzymes to different 
genomic sites. In order to avoid screening complete genomes, knowledge gained from epigenomic profiles 
should be integrated into the library design. For example, designing gRNA libraries focusing on informative 20 
regions identified from integrative analysis of epigenomic profiles would greatly reduce the complexity of 
libraries and thus enhance the power of such epigenomic screens.  
 
As outlined in Figure 5c such screens will enable the identification of the subset of causal epigenetic marks 
amongst the many with inferred function. gRNA libraries representing loci identified in epigenomic profiles 25 
are introduced into cells expressing the relevant dCas9–modifier fusion. Those cells responding to an 
individual modification with a suspected phenotypic change will be separated from the bulk population 
(through selection, fluorescence-activated cell sorting (FACS) or cellular behavior) and used to gain 
17 
 
information about the individual gRNAs those cells received.  It is difficult to predict today which cellular 
phenotypes will be most susceptible for these approaches, however it is not unreasonable to start with those 
cellular phenotypes that are clearly epigenetic, easy and accurate to measure and ideally reversible (e.g. 
cell identity, cell cycle control, migration).  
 5 
In principle, epigenetic screens are feasible already today. For example, instead of genetically mutating a 
large number of enhancers through CRISPR-based genetic screening 61, epigenome editing tools could be 
used to manipulate chromatin modifications at these sites. On a small-scale such an epigenetic screen has 
already been conducted. Kearns et al. used published profiles of ES- and Epiblast-like cells (EpiLCs) to 
generate a list of candidate enhancers with potential roles in pluripotency. Targeting dCas9–LSD1 to one 10 
of these active enhancers mediated H3K4 de-methylation and abrogated transcription of associated 
genes112, hence the authors then used this system to screen eight candidate enhancers to investigate the 
effect of H3K4 de-methylation on ESC self-renewal 112. Scaling up such epigenome editing approaches to 
epigenome-wide screens has the potential to reveal many (and eventually all) epigenetic marks and features 
playing causal roles in a given cellular phenotype (Figure 5c).  15 
 
To make epigenome editing universally applicable, several issues have yet to be resolved: First and 
foremost, information about the distribution of the majority of chromatin features is still missing. Only a 
small minority of epigenomic features has been profiled so far, and some of the profiling technologies used 
at the time have become outdated and/or evolved (e.g. epigenomics on the single cell level) 113 indicating a 20 
continued need for profiling efforts. Moreover, the toolset of efficient dCas9–chromatin modifier fusion 
proteins has to be expanded. There is, for example, to date no validated tool for the successful addition or 
removal of H3K27 methylation, which is one of the most frequently profiled chromatin marks in human 
cells. Furthermore, gRNA libraries specifically targeting regions that harbour particular chromatin 
modifications are not yet available. However, simple methods for the generation of ultra-high-complexity 25 
or even genome-wide gRNA libraries have already been established 114, 115. And finally, to make the most 
of the new molecular tools discussed in this review, reliable in vitro models or in vivo approaches that 
allow assessment (and selection) of induced phenotypic changes have to be developed 103. Considering the 
rapid progression of CRISPR-based technology during recent years it is not inconceivable that 
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comprehensive functional interrogation of chromatin marks and features could become a common 




In this review, we have traced some of the seminal studies and approaches showing the way towards 
functional analysis of epigenomic marks and features which remains to be one of the main challenges for 
epigenomics. Based on current evidence, the key innovation promising to deliver this breakthrough will 
almost certainly be based on epigenome editing and, in particular, on the ability to conduct epigenome-
wide screens to identify causal chromatin features out of the myriad of those with inferred function 10 
identified through epigenomic profiling and data integration. Returning to the analogy of an epigenetic 
landscape from which we started, epigenomic engineering promises to turn the static landscape depicted 
by Waddington into a dynamic environment as illustrated in the contemporary animation (Figure 1B; 
Supplementary information S1 (movie)) created by the resident artists of EpiGeneSys (see online links), 
the European Network of Excellence for Epigenetics and Systems Biology. In the context of this review, 15 
the pulling of the strings represents the approaches discussed here to screen for chromatin marks that 
causally influence cellular fate in health and disease. Based on the tremendous progress made to date, it is 
perhaps not surprising that expectations are running high to translate any fledgling new insights already 
into novel medicines and treatments. While epigenetic marks and drugs are already in clinical use as 
biomarkers and treatments respectively for certain types of cancer, epigenome editing has not yet been used 20 
therapeutically. In addition to functional candidates and technical improvements this step would require 
ethical considerations similarly to those currently discussed for genome editing technology 116. With these 
promising developments in mind, does this mean that epigenomic profiling is essentially completed and a 
thing of the past? Certainly not, since new marks and features are still being discovered and new or 
improved profiling technologies are still being developed. It will, however, be interesting to explore which 25 
type of profiling turns out to be most informative for which field of research and, in particular, for the 





Box 1 | Summary of key early epigenetic experiments addressing function of DNA methylation. 
Chromatin can be altered in a large variety of ways, but only a few chromatin features have been shown to 
functionally involved in gene expression. The chromatin mark to get first (and to date still most) attention 5 
is DNA methylation. Discovered in the late 1940s as a modification of cytosine bases 24, 117 it became early 
on a prime candidate for an epigenetic effector, because of its uneven distribution in the genome and its 
heritability 118-120. First correlations between gene expression and DNA methylation were reported on a 
series of highly informative model loci (e.g. chicken and mammalian globin genes, the X-chromosome 
inactivation centre (XIC), genomic imprinting and virus, transgene or retrovirus silencing) 121-123. However, 10 
it was only after the use of inhibition 124 or deletion of DNA methyltransferases 125, in vitro methylation of 
DNA 126 or genetic deletion of differentially methylated regions 51, that functional connections could be 
deducted. Because of epigenomics and transcriptomics we know today that the relationship between DNA 
methylation and gene expression is likely to be more complicated than initially suspected. While marks at 
certain positions correlate with silencing of some genes (e.g. in colon cancer) 127, others are rather 15 
uninformative or even occur at active genes 128-131.     
 
Box 2 | Profile types and categories (including embedded Figure 3). 
The number of epigenomic marks and features that can be profiled is inherently a moving target. 
Consequently, the profile types and 6 categories illustrated in Figure 3 and explained here are incomplete 20 
and subject to change. The cartoon of chromatin depicts common marks and features that are further 
grouped into six boxed categories (see Glossary for detailed descriptions) listed on the right side. On the 
DNA level, modifications have been shown to occur at positions C5 or N3 on cytosines and at position N6 
on adenines and to be catalysed either enzymatically by DNA methyltransferases (DNMTs) for 5mC or 
chemically for 3mC. The mechanism of modification for 6mA is still unknown. As part of an active 25 
demethylation pathway mediated by TET enzymes, 5mC can be further modified by stepwise oxidation to 
5hmC, 5fC and 5caC, respectively. Because of their versatility, profiling of DNA modification can be 
configured for multiple readouts, including differentially methylated positions (DMPs) or regions (DMRs), 
20 
 
differentially variable positions (DVPs), partially methylated domains (PMDs) and blocks of comethylation 
(COMETs) 132, 133.  On the histone level, 12 enzymatically catalysed modifications (see Figure 3) have been 
shown to occur at over 130 post transcriptional modification sites (PMTs) at the tails of the four core 
histones (H2A, H2B, H3 and H4) and some 30 histone variants 134. Recently, further modifications 
(H3K64ac and H3K122ac) were also observed in the globular domain of H3 and shown by epigenome 5 
editing to define a new class of enhancers 135 adding to the evidence that our current knowledge of 
epigenetic modifications is far from complete. Despite their extraordinary variety, histone modifications 
are profiled essentially by a single assay and readout (ChIP-seq). On the feature level, we distinguish three 
categories of structurally different features for which multiple profiling assays (see Glossary) have been 
developed depending on the complexity of the readout. For profiling nucleosome occupancy, DNase1 10 
footprinting has been the assay of choice in the past to identify cell-type-specific regulatory elements but 
ATAC-seq 136 is now becoming increasingly popular due to its simpler work flow and its ability to work 
with substantially fewer cells. Different implementations of chromatin conformation capture assays (see 
Glossary) are being used to connect enhancers to the promoters they control as well as for profiling of 
chromatin insulators that block those interactions. Especially when integrated with DNA and or histone 15 
modification profiles, profiling with HiC 137 allows segmentation of the epigenome into a variety of 
chromatin domains (e.g. Topologically associated domains (TADs)). On the transcriptome level, a 
multitude of noncoding RNAs have been mapped, which in some cases can regulate gene expression 138, 
while profiling of RNA modifications (for example occurring at positions C5 or N3 on cytosines and at 
positions N1 and N6 on adenines) has not yet been systemically analyzed. In the upper left panel, base 20 
positions where methylation has been found to date in DNA or RNA are marked in orange. Because of the 
complexity of combinatorial possibilities, there is currently no tissue or cell type for which all marks and 
features have been profiled. The largest collection of tissues and cell types for which at least 9 core marks 
(shown in the lower left panel) have been consistently profiled are those also referred to as IHEC reference 
epigenomes. 25 
 
Figure 1 | Evolving views on the Waddington landscape. 
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(A) Epigenetic landscape as depicted by C.H. Waddington. In this analogy epigenetics influences cellular 
fate during development analogous to gravitational forces on a defined landscape. (B) Contemporary 
version of the Waddington landscape depicting epigenome editing (see also Supplementary information 
S1 (movie)). Epigenetic and epigenomic manipulation promises to dynamically change the landscape and 
thus, cellular phenotypes. 5 
 
Figure 2 | Schematic indicating which experimental approaches are targeting which level of function. 
While epigenomic profiling alone results in descriptive information, integration of multiple layers of 
information allows to infer function. Genetic manipulation can reveal relevance of epigenetic features, 
however only indirectly. Currently used methods for epigenetic manipulation of single marks or features 10 
can reveal causality, future approaches, will enable us to identify novel functional marks in an epigenomic 
scale (epigenetic screens). 
 
Figure 3 | Complexity of epigenomic profiling (integrated in Box 2).  
 15 
Figure 4 | Schematic of multi-dimensional profile integration.  
Integration is achieved in two steps. First, missing data are imputed using profiles from the same (vertical 
dashed box) and/or closely related samples (horizontal dashed box). Currently, histone modification and 
transcription factor (TF) binding profiles are mostly used for imputation but there is no reason why other 
profiles cannot be used as well. Second, additional, non-epigenomic data (not discussed here but equally 20 
important) can be added as appropriate and the entire data set per sample aggregated and segmented into 
chromatin states, ranging from 2 (as illustrated here) to >50 states, depending on context and complexity 
139 . While the majority of current epigenomic data has been derived from healthy samples, data from 
diseased samples and further integration with muliti-omics data and pathways can be expected to follow 
soon e.g. as part of the recently  established H2020 MultipleMS and SYSCID Consortia focusing on 25 
multiple sclerosis and chronic inflammatory diseases, respectively. For more details on the current strategy 




Figure 5 | Strategies for epigenome editing.  
(A) A chromatin modifier (or its minimal catalytic domain) is fused to a targetable DNA binding domain 
(here showing dCas9). The enzymatic activity of the chromatin modifier is directed towards a particular 
DNA sequence where it can either add or remove chromatin marks from histones or DNA depending on 
the nature of the chromatin modifier. This system allows investigating how editing of a mark at a particular 5 
site affects the expression of associated genes. Read-outs can be at the level of RNA, protein or phenotype 
as illustrated. (B) Schematic illustrating how targeted epigenome editing can be used to build a hierarchy 
of functional marks. A range of different chromatin modifiers are fused to the same DNA binding domain 
and targeted to the same site. The effect of the engineered chromatin modification on associated genes can 
be measured to establish a hierarchy of chromatin features. (C) Using epigenome editing allows identifying 10 
chromatin modifications impacting cellular phenotypes. Prior knowledge about the genes involved in 
regulating particular phenotypes and the location of regulatory elements can be used to design pooled 
gRNA libraries enabling targeted screens. If particular gRNAs target the chromatin modifier to functional 
sites, phenotypic changes are induced, allowing selection and determination of gRNA sequences. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































           
 
 
Supplementary movie file 1 | Contemporary version of the Waddington landscape (see also Figure 1). 





Blocks of comethylation identified by methylome segmentation 
 10 
Pooled screens: 
Approaches in which cells receiving the screening library (e.g. gRNA pools) are grown and selected 
together for a phenotypic change. 
  
DNase1-hypersensitive sites:    15 
25 
 




Formaldehyde Assisted Isolation of Regulatory Elements followed by sequencing is a technique that uses 5 
the solubility of open chromatin in the aqueous phase during phenol-chloroform extraction to identify sites 
of open chromatin. 
 
ATAC-seq:  
Assay for transposase-accessible chromatin sequencing is a method to identify regions of open chromatin 10 




Chromatin immunoprecipitation followed by sequencing. A method for mapping the distribution of histone 15 
modifications or chromatin-associated proteins or transcription factors along the genome. DNA and protein 
are cross-linked and an antibody specific to the protein of interest is used to enrich for DNA sequences 
bound to this protein. These are then identified by sequencing revealing the genome-wide profile of the 
protein of interest. 
 20 
GWAS:  
Genome-wide association studies aim to identify genetic loci associated with an observable trait, disease 
or condition. 
 
SNP:  25 
Single nucleotide polymorphism is a single base-pair difference in the DNA sequence of individual 





Topologically associated domains are regions of chromatin in which loci frequently interact with each 
other, based usually based on evidence from Chromosome conformation capture techniques. Loci located 
in different TADs do not come into contact frequently. 
 5 
Chromosome conformation capture: 
A group of techniques (3C, 4C, 5C, HiC, ChiAPet) that are used to map physical interactions between 
segments of DNA in three-dimensional space. 
 
HiC: 10 




Transcription activator-like effectors are DNA-binding proteins that have a modular architecture with each 15 
module ( ~34 amino acids) recognising a single nucleotide in a DNA sequence and therefore can be 
engineered to bind to a DNA sequence of choice. 
 
Zinc-finger: 
Modular DNA binding protein that can be engineered to bind to a sequence of choice 20 
 
CRISPR–Cas9: 
Clustered regularly interspaced short palindromic repeats–CRISPR-associated protein 9 are components of 
a bacterial defense system against viruses. 
 25 
Cas9: 
Cas9 stands for CRISPR-associated protein 9. It is useful for genome engineering because it can be guided 





dCas9 is the nuclease-dead version of Cas9, which can no longer produce double-strand breaks. 
 
gRNA: 5 
The gRNA is an artificial fusion of CRISPR (clustered regularly interspaced short palindromic repeat) RNA 




Fluorescence-activated cell sorting is an experimental method to measure a fluorescence-based signal (from 
a reporter or antibody staining) emitted from individual cells of a population that can also be used to isolate 
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